7th Circ. Declines To Revive Humira 'Patent Thicket' Claims

By Hailey Konnath and Bryan Koenig · August 1, 2022, 8:08 PM EDT

A Seventh Circuit panel on Monday refused to revive landmark private antitrust claims from Humira buyers accusing pharmaceutical giant AbbVie of using a "patent thicket" to illegally shield the blockbuster immunosuppressant...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Mayor and City Council of Baltimore, et al v. AbbVie Inc., et al

Case Number

Court

Appellate - 7th Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 30, 2020

Recent Articles By Hailey

July 05, 2024
9th Circ. Backs Remand Of Cedars-Sinai Patient Data Suits
July 03, 2024
HHS Scores Early Win In Boehringer's Medicare Pricing Suit
July 01, 2024
State AGs Get Stay Lifted In Generic Drug Pricing Litigation
June 27, 2024
OptumRx Agrees To Pay $20M To Resolve DOJ Opioid Claims
June 27, 2024
ACLU Says Mich. Can't Ban Medicaid Coverage Of Abortions
June 18, 2024
Novant Pays $6.7M For Sharing Patient Data With Facebook
June 10, 2024
Baltimore Lands $45M Deal With Allergan In Opioid Litigation
June 07, 2024
Motley Rice Allocated Biggest Share Of $2B Opioid Fees
June 04, 2024
Divided 9th Circ. Reverses Sutter Health Antitrust Trial Victory
May 31, 2024
Caremark Cut Loose From CVS Price-Gouging Case